Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...

United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell therapies focused on the thymus.

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...

The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

Buying Memo is the latest chapter in Ipsen’s ongoing push to pad out its pipeline across its three priority areas of rare disease, oncology and neuroscience ...